News

Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland, Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating...

Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE,...

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ --...

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS...

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE,...

New generation of SOPHiA DDMTM integrates latest advancements in data processing and technology to deliver elevated experience and capabilities to customers BOSTON and ROLLE, Switzerland, Sept. 4,...

SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Morgan Stanley Healthcare Conference and the 9th Annual TD...

Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland, Aug. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss BOSTON and ROLLE, Switzerland, Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),...

The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland, July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal year...

The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing BOSTON and ROLLE, Switzerland, July 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland, June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS...

The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, June 13, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland , May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS...

In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland , May 29, 2024 /PRNewswire/ -- SOPHiA...

The hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™ Platform BOSTON and ROLLE, Switzerland , May 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

The SOPHiA DDM™ Platform will help broaden the hospital's cancer testing and diagnostic capabilities BOSTON and ROLLE, Switzerland , May 16, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),...

Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed BOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnostics throughout Africa BOSTON and ROLLE, Switzerland , April 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),...

European-based Unilabs has deployed the SOPHiA DDM™ Platform across its network in Switzerland to support cancer diagnostics and treatment BOSTON and ROLLE, Switzerland , April 17, 2024...

The companies will join forces to advance the use of precision medicine on a global scale BOSTON and ROLLE, Switzerland , April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

The Chile-based Laboratory is using SOPHiA GENETICS' platform to advance its research capabilities with blood disorders BOSTON and ROLLE, Switzerland , April 2, 2024 /PRNewswire/ -- SOPHiA...

University of Saskatchewan's (USask) Advanced Diagnostics Research Laboratory will use SOPHiA DDM™ Platform to advance research on ovarian cancer care BOSTON and ROLLE, Switzerland , March 20, 2024

New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland , March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:...

Strong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new customer additions in Q4, and 36% cash burn decline in FY 2023 BOSTON and ROLLE, Switzerland, March 05, 2024...

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID , Feb. 7, 2024 /PRNewswire/ --...

The company announced Bioma4me has implemented SOPHiA DDM™ to support its rare disorder testing capabilities BOSTON and ROLLE, Switzerland , Jan. 25, 2024 /PRNewswire/ -- SOPHiA GENETICS...

RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel BOSTON and ROLLE, Switzerland , Jan. 18, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized...

Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology,...

Insights from multimodal datasets on the platform fuel cancer research in Canada BOSTON and ROLLE, Switzerland , Jan. 8, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

The Hospital will use SOPHiA GENETICS technology to streamline workflows and expedite research BOSTON and ROLLE, Switzerland , Dec. 21, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

World-class liquid biopsy testing will be available to SOPHiA GENETICS customers BOSTON and ROLLE, Switzerland , Dec. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

Through the expanded relationship CHU de Nîmes will advance its research of rare and inherited diseases through pharmacogenomics BOSTON and ROLLE, Switzerland , Nov. 30, 2023 /PRNewswire/ --...

Largest health center in Italy uses SOPHiA DDM™ Platform on Microsoft Azure to expand data-driven medicine capabilities while ensuring accuracy and security BOSTON and ROLLE, Switzerland , Nov....

The SOPHiA DDM™ Platform used by IHG PAS to advance its research of male infertility BOSTON and ROLLE, Switzerland , Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

Record results on growth acceleration, significant improvement in operating loss and cash burn BOSTON and ROLLE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a...

World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON and ELMWOOD PARK, N.J., and ROLLE, Switzerland , Nov. 7, 2023...

The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science BOSTON and ROLLE, Switzerland , Oct. 18, 2023...

The hospital will use the SOPHiA DDM™ Platform to further its work with myeloid disorders and advance the development of precision medicine BOSTON and ROLLE, Switzerland , Sept. 29, 2023 /PRNewswire

The SOPHiA DDM™ Platform will help Laboratorio Curie advance its research into BRCA gene mutations BOSTON and ROLLE, Switzerland , Sept. 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),...

With the help of the SOPHiA DDM™ Platform, IRST has introduced a new diagnostic kit that will support data- driven treatment planning for a dvanced ovarian cancer BOSTON and ROLLE, Switzerland ,...

The hospital is using the SOPHiA DDM™ Platform to advance the research of Homologous Recombinati on Repair Mutated Cancers BOSTON and ROLLE, Switzerland , Aug. 30, 2023 /PRNewswire/ -- SOPHiA...

Gustave Roussy uses SOPHiA DDM™ Platform to empower confident, data-driven medicine in the fight against cancer BOSTON and ROLLE, Switzerland , Aug. 22, 2023 /PRNewswire/ -- SOPHiA GENETICS...

The Hospital will use the SOPHiA DDM™ Platform to advance its research and diagnosis of blood cancers BOSTON and ROLLE, Switzerland , Aug. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:...

Robust growth and efficient expense execution continues BOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a...

The School of Medicine will use the SOPHiA DDM™ Platform to expand its hematologic testing program for blood cancers BOSTON and ROLLE, Switzerland , Aug. 8, 2023 /PRNewswire/ -- SOPHiA GENETICS...

SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the second quarter of fiscal 2023 before U.S....

CSM is using the SOPHiA DDM™ Platform to expand its next-generation sequencing (NGS) offerings BOSTON and ROLLE, Switzerland , July 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

SOPHiA DDM™ Platform will bring next-generation sequencing in-house and help further research on hematologic malignancies BOSTON and ROLLE, Switzerland , July 7, 2023 /PRNewswire/ -- SOPHiA...

SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, is pleased to announce that its Annual General Shareholders Meeting...

SOPHiA GENETICS technology to aid research associated with hereditary cancers and disorders BOSTON and LAUSANNE, Switzerland , June 22, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

SOPHiA GENETICS technology aids NOMAD Genetics in the advancement of its cancer research capabilities BOSTON and LAUSANNE, Switzerland , June 15, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:...

As a leader in data-driven medicine , SOPHiA GENETICS lends its expertise to support White House Cancer Moonshot BOSTON and LAUSANNE, Switzerland , June 2, 2023 /PRNewswire/ -- SOPHiA GENETICS...

Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland , May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

SOPHiA DDM™ deep-learning algorithm will help determine HRD status of tumors for Institute of Oncology Ljubljana researchers BOSTON and LAUSANNE, Switzerland , May 24, 2023 /PRNewswire/ --...

SOPHiA GENETICS technology will help increase cancer research abilities BOSTON and LAUSANNE, Switzerland , May 16, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software...

In just one year of using SOPHiA DDM™ HRD, Dasa reaches 2,000 samples analyzed BOSTON and LAUSANNE, Switzerland , May 8, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

Strong growth momentum and efficient expense execution continues BOSTON and LAUSANNE, Switzerland, May 09, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software...

Fourth Quarter Revenue Growth Accelerates; Operating Losses Notably Moderate BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--Mar. 7, 2023-- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native...

Sustainable growth momentum evident despite foreign exchange headwinds BOSTON and LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native...

The agreement is to expand and reinforce data-driven medicine through the SOPHiA DDM™ health data analysis platform available with Microsoft Azure GENEVA , Nov. 1, 2022 /PRNewswire/ -- SOPHiA...

Highlights include: a memorandum of understanding with Memorial Sloan Kettering Cancer Center and a novel new partnership with Boundless Bio, a next-generation precision oncology company SOPHiA...

Steady Operational Performance Amidst Macroeconomic Headwinds BOSTON and LAUSANNE, Switzerland, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company...

SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), is pleased to announce the Annual General Meeting ("the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD,...

SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), today announced that the Company has published its first Environmental, Social and Governance Impact Summary ("ESG Impact Summary"). The ESG...

Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of...

SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced three abstracts accepted for poster presentation and one for online publication at the 2022 American Society of...

Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq:...

SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the...

SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position as one of...

Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 2021 2022 Guidance Reaffirmed BOSTON and LAUSANNE, Switzerland, March 15, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH),...

The intended collaboration aims to help improve patient care by enhancing next-generation sequencing research for cancer care and expanding data sources for precision medicine. BOSTON, ALISO...

SOPHiA GENETICS (Nasdaq: SOPH) today announced that SOFIVA GENOMICS, which is one of the largest genetic testing companies in Taiwan aiming to provide genetic testing to clinicians, is the first...

The SOPHiA DDM HRD Solution offers cost-effective, accurate, reliable, timely, and easily implementable in-house results to empower better clinical research decisions BOSTON and LAUSANNE, Switzerland,

SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan, to support their molecular profiling by...

SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, have announced, in conjunction with Assises de Génétique, an extension of their partnership with Institut Paoli Calmettes (IPC),...

SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that democratizes data-driven medicine, today announced that Ken Freedman has been appointed...

SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of...

SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced key additions to their leadership team with the...

Study to leverage deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of...

Symposium to address how new AI-powered analytic and workflow solutions for clinical and biopharma markets are advancing data-driven medicine Symposium encapsulates SOPHiA GENETICS and GE...

Third quarter year-over-year revenue growth of 45%; executed Master Alliance Agreement with GE Healthcare BOSTON and LAUSANNE, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA...

New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq:...

BOSTON and LAUSANNE, Switzerland, Sept 9, 2021 — SOPHiA GENETICS SA (NASDAQ: SOPH), today reported financial results for the three months ended June 30, 2021. Recent Highlights Revenue was $10.2...

(Family Features) When it comes to balancing heart-healthy meals with appealing flavors, it's important to lean on nutritious ingredients that pack mouthwatering taste. For example, grapes are a...

Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...

Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...

Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...

Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi,...

ACME Inc. (NYSE: ) today reported financial results for the fourth quarter and full year ended December 31, 2010. For the fourth quarter 2010, we...

Body copy of news release

Body copy of news release.